Nidus MB Technologies is at the forefront of tissue chip and microphysiologic systems (MPS), leading efforts to reduce, refine and replace animal models in drug development, in line with the new 2025 NIH and FDA directives. Our patented Microbubble Arrays (MBA™ ) technology and proprietary assays provide high throughput screening (HTS) solutions using cultured single cells, complex microtissues and organoids for disease modeling, drug screening and toxicology testing.
What Sets Microbubble (MB) Array Apart:
Rapid 3D Spheroid Formation
Spherical microenvironments enable swift cell aggregation and spheroid/organoid development.
Enhanced Autocrine/Paracrine Signaling
Promotes the local concentration of cell-secreted factors, supporting natural cellular communication for robust tissue formation.
No Necrotic Core Formation
Ensures uniform viability and function across the entire microtissue.
Scaffold & ECM Integration
Compatible with incorporation of extracellular matrix (ECM) components or scaffolding materials into MBs to better mimic native tissue environments.
High-Throughput & Scalable
Validated for large-scale generation-up to 3,840 microtissues per 96-well plate- ideal for drug screening and discovery.
User-Friendly Media Exchange
Designed for effortless, non-disruptive manual media changes
Spheroid Retention
Cells and spheroids remain stably confined within MBs: Once in the MB, always in.
Automation-Compatible
Seamless integration with robotic liquid handling and imaging systems.
Dynamic Culture Capability
Supports static and perfused culture formats, allowing flexibility in experimental design.
Cost-Effective Solution
Highly efficient and economical for both academic and industrial applications